Drug Trial Radar · NCT06755684
Neoadjuvant Befotertinib Combined Bevacizumab or Platinum-based Double Chemotherapy for Resectable Locally-advanced EGFR Mutation-positive Non-Small Cell Lung Cancer
Last checked: Nov 19, 2026Latest source record: Jan 6, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
Nov 7, 2024
Primary completion
Dec 31, 2025
Study completion Dec 31, 2028
Sponsor
- Lead sponsor
- Peng ZhangAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jan 1, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study targeted patients with resectable stage II-IIIA non-small cell lung cancer with EGFR mutation
Conditions
- EGFR
- Non-Small Cell Lung Cancer
- Locally Advanced Non-Small Cell Lung Cancer
- Pemetrexed
- Carboplatin
- Bevacizumab
- Antineoplastic Agents
- Tyrosine Kinase Inhibitor
Interventions
Befotertinib combined BevacizumabDrug
Befotertinib combined Bevacizumab
Befotertinib combined platinum-based double chemotherapyDrug
Befotertinib combined platinum-based double chemotherapy
Primary outcomes
What the sponsor says the trial is designed to measure.
- Major pathologic response (MPR)Time frame: up to 4 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai Pulmonary Hospital
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.